A new liquid biopsy assay combining a microRNA signature and a pancreatic cancer biomarker has shown 97% accuracy in detecting stage I/II pancreatic ductal adenocarcinoma. Developed by Ajay Goel and colleagues, the test was tested in Japan, China, South Korea, and the US, with promising results. Adding the biomarker carbohydrate antigen 19-9 increased accuracy to 97%. The technology has been licensed for commercial development, with potential use in screening high-risk patients. Further validation efforts are ongoing, including screening thousands of blood samples. Early detection of pancreatic cancer could significantly improve treatment outcomes. Funding for the research was provided by the National Cancer Institute.
Source link
Liquid Biopsy Shows Promise in Detecting Pancreatic Cancer
